LUND, SWEDEN / ACCESSWIRE / August 29, 2024 / BioInvent International (STO:BINV)

"The presentation of promising results from our two lead drug candidates at the ASCO Annual Meeting showcased their potential as first-in-class immunomodulatory agents and kicked off a data-rich period for BioInvent where we expect to report results from all six of our clinical programs." - Martin Welschof, CEO of BioInvent.

EVENTS IN THE SECOND QUARTER
? (R) Additional Phase 1/2a data for BI-1206 with rituximab in NHL presented at EHA 2024, showcasing promising early efficacy data from the SC arm
? (R) Clinical efficacy and safety for anti-TNFR2 agent BI-1808 presented at ASCO 2024 showing single agent activity of BI-1808, a potential new class of immunomodulatory agent
? Patent for BI-1808 approved in China
? (R) Phase 1 data for BI-1206 in combination with KEYTRUDA? (pembrolizumab) in solid tumors presented at ASCO 2024; showing responses in melanoma patients who previously failed on anti-PD1 therapy
? Poster highlighting model-informed early clinical development of anti-TNFR2 agent BI-1808 presented at PAGE 2024, supporting dose selection and optimization of clinical development
? New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA? (pembrolizumab)

EVENTS AFTER THE END OF THE PERIOD
? The subcutaneous formulation (SC) of BI-1206 selected for the upcoming Phase 2a study in combination with rituximab and acalabrutinib for the treatment of NHL
? Notice of Allowance received from USPTO for BI-1910 patent application
? New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1607, the company's second anti-FcyRIIB antibody in combination with KEYTRUDA? (pembrolizumab) and ipilimumab
? Two programs to be presented at ESMO 2024: the company's second anti-TNFR2 antibody BI-1910 and the oncolytic virus BT-001 armed with BioInvent's anti-CTLA-4 antibody

(R)= Regulatory event

FINANCIAL INFORMATION
Second quarter 2024

• Net sales, SEK 4.6 (13.1) million

• Profit/loss after tax, SEK -137.3 (88.3) million

• Profit/loss after tax per share before and after dilution, SEK -2.09 (1.34)

• Cash flow from operating activities, SEK -119.2 (-84.1) million

• Liquid funds, current and long-term investments at the end of the period, SEK 1,090.3 (1,461.7) million

January - June 2024

• Net sales, SEK 10.6 (29.3) million

• Profit/loss after tax, SEK -215.3 (-162.1) million

• Profit/loss after tax per share before and after dilution, SEK -3.27 (-2.47)

• Cash flow from operating activities, SEK -185.1 (-163.1) million

• Liquid funds, current and long-term investments at the end of the period, SEK 1,090.3 (1,461.7) million